Comparison · NCT00096785-e7d2c2b0
Entecavir vs Adefovir: Viral Load Undetectable (HBV DNA <300 Copies/mL)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Entecavir vs Adefovir: Viral Load Undetectable (HBV DNA <300 Copies/mL). Trial comparisons, record NCT00096785-e7d2c2b0. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00096785-e7d2c2b0
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.576 | 0.408 | 0.728 | wilson | |
| Risk in group 2 | 0.188 | 0.0889 | 0.353 | wilson | |
| Risk difference, group 1 minus group 2 | 0.388 | 0.153 | 0.569 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 3.07 | 1.41 | 6.69 | log | |
| Odds ratio, group 1 over group 2 | 5.88 | 1.91 | 18.1 | log | |
| Number needed to treat, for one more participant with the outcome on Entecavir than on Adefovir | 2.58 | 1.76 | 6.55 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Entecavir | ETV 0.5 mg once daily (QD) | 19 | 33 | OG000 |
| Group 2 | Adefovir | ADV 10 mg QD | 6 | 32 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Viral Load Undetectable (HBV DNA <300 Copies/mL)
- Description
- Number of Subjects with HBV DNA \<300 copies/mL by Roche COBAS® Amplicor (limit of quantitation 300 copies/mL)
- Time frame
- Week 48
- Population
Treated participants who had both baseline and Week 12 HBV DNA measurements and who received the randomized treatment. 1 participant randomized to ADV actually received ETV and is not counted in secondary efficacy analyses.
Source ClinicalTrials.gov
Trial
- Title
- Comparative Trial of Entecavir Versus Adefovir in the Treatment of Chronic Hepatitis B Infection
- NCT number
- NCT00096785
- Phases
- PHASE3
- Conditions
- Hepatitis B, Chronic Disease
- Interventions
- entecavir, adefovir
- Lead sponsor
- Bristol-Myers Squibb
- Results first posted
- 2010-01-06
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00096785?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00096785-e7d2c2b0